327 related articles for article (PubMed ID: 21767697)
21. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
22. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
23. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
Castellanos González M; Pérez Carreras M; Muñoz Gómez R; Castellano Tortajada G
Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
[No Abstract] [Full Text] [Related]
24. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.
Kim ET; Kim LH; Lee JI; Chin HS
Jpn J Ophthalmol; 2009 Nov; 53(6):598-602. PubMed ID: 20020238
[TBL] [Abstract][Full Text] [Related]
25. [Information for patients. Treatment of acute hepatitis C].
Otón Nieto E
Rev Esp Enferm Dig; 2011 Oct; 103(10):549. PubMed ID: 22054273
[No Abstract] [Full Text] [Related]
26. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
[No Abstract] [Full Text] [Related]
27. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C: a review of diagnosis, management, and ocular complications from treatment.
Tsolakos A; Zalatimo N
Optometry; 2003 Aug; 74(8):517-23. PubMed ID: 12926825
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience.
Paschos P; Vlachaki E; Pasvanti C; Sinakos E; Kalpaka A; Klonizakis P; Perifanis V
Acta Haematol; 2011; 126(4):231-3. PubMed ID: 21934299
[No Abstract] [Full Text] [Related]
30. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
[No Abstract] [Full Text] [Related]
31. [Exceptional pancytopenia secondary to treatment with pegylated interferon and ribavirin].
Wikman Jorgensen PE; Jover Díaz FM; Cuadrado Pastor JM
Gastroenterol Hepatol; 2007 Apr; 30(4):253. PubMed ID: 17408558
[No Abstract] [Full Text] [Related]
32. [Retinopathy during interferon treatment in combination with ribavirin for chronic hepatitis C].
Nakamura T; Takahashi H; Koike N; Mitsutaka M; Soda M; Kimu M
Nippon Ganka Gakkai Zasshi; 2005 Nov; 109(11):748-52. PubMed ID: 16363669
[TBL] [Abstract][Full Text] [Related]
33. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
34. Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin.
Papastergiou V; Skorda L; Lisgos P; Karatapanis S
Acta Gastroenterol Belg; 2011 Dec; 74(4):582-4. PubMed ID: 22319972
[No Abstract] [Full Text] [Related]
35. Is screening for interferon retinopathy in hepatitis C justified?
Cuthbertson FM; Davies M; McKibbin M
Br J Ophthalmol; 2004 Dec; 88(12):1518-20. PubMed ID: 15548803
[TBL] [Abstract][Full Text] [Related]
36. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Lopukhova NL
Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
[No Abstract] [Full Text] [Related]
37. Risk factors for retinopathy associated with interferon alpha-2b and ribavirin combination therapy in patients with chronic hepatitis C.
Okuse C; Yotsuyanagi H; Nagase Y; Kobayashi Y; Yasuda K; Koike K; Iino S; Suzuki M; Itoh F
World J Gastroenterol; 2006 Jun; 12(23):3756-9. PubMed ID: 16773695
[TBL] [Abstract][Full Text] [Related]
38. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
Iacob SA; Petrescu AM; Iacob DG
Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
[TBL] [Abstract][Full Text] [Related]
39. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
Verma P; Dayal S; Jain VK; Amrani A
J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
[TBL] [Abstract][Full Text] [Related]
40. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]